| Symbol | ACRV |
|---|---|
| Name | ACRIVON THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 480 ARSENAL WAY,SUITE 100, WATERTOWN, Massachusetts, 02472, United States |
| Telephone | 6172078979.0 |
| Fax | — |
| — | |
| Website | https://www.acrivon.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The companys Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. Additional info from NASDAQ: |
Miller Mary 🔴 sold 558 shares of Acrivon Therapeutics, Inc. (ACRV) at $1.78 Transaction Date: Apr 17, 2026 | Filing ID: 001768
Read moreAcrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
Read moreAcrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Read moreNew Form SCHEDULE 13D/A - Acrivon Therapeutics, Inc. <b>Filed:</b> 2026-03-23 <b>AccNo:</b> 0001346824-26-000081 <b>Size:</b> 15 KB
Read more(30% Negative) ACRIVON THERAPEUTICS, INC. (ACRV) Reports Q1 2026 Financial Results
Read moreAcrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Read moreNew Form S-8 - Acrivon Therapeutics, Inc. <b>Filed:</b> 2026-03-19 <b>AccNo:</b> 0001193125-26-115150 <b>Size:</b> 190 KB
Read moreNew Form 10-K - Acrivon Therapeutics, Inc. <b>Filed:</b> 2026-03-19 <b>AccNo:</b> 0001193125-26-115123 <b>Size:</b> 12 MB
Read moreAcrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
Read moreAcrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06667141 | Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors | Phase1 | Specific Advanced Solid Tumors | Recruiting | 2024-10-08 | 2026-12-12 | ClinicalTrials.gov |
| NCT06597565 | A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC | Phase2 | Head and Neck Squamous Cell Carcinoma | Recruiting | 2024-09-25 | 2028-08-23 | ClinicalTrials.gov |
| NCT05548296 | A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Phase2 | Endometrial Adenocarcinoma | Recruiting | 2022-08-29 | 2027-04-30 | ClinicalTrials.gov |